EurocanPlatform 1 st annual meeting WP5: Targeting the DNA damage response
|
|
- Ada Gilmore
- 5 years ago
- Views:
Transcription
1 EurocanPlatform 1 st annual meeting WP5: Targeting the DNA damage response Brussels, December 16, 2011 Alan Ashworth, ICR London Jos Jonkers, NKI Amsterdam Jiri Bartek, DCS Copenhagen
2 WP5 Objectives Validated diagnostic tests for homologous recombination defects and PTEN deficiency Novel targets for therapy in Triple Negative breast cancer
3 Triple-Negative Breast Cancer (TNBC) BRCA1-mutated BC (2-4%) TNBC (15% in Caucasian) (39% in Afr-Am) BRCA1-like BC (10-20%?) TNBCs have poor prognosis and rapid relapse TNBCs cannot be treated with endocrine agents or HER2 targeted therapy because they are negative for ER, PR and ERBB2 BRCA1-deficient BCs can be treated with DNA-damaging agents or PARPi
4 Mouse models of human cancer Genetically engineered mouse models (GEMMs) Human tumor xenograft models (xenopatients) Additional mutations Tumors 1 st Intervention Relapses 2 nd Intervention Cross-resistance? Mechanisms? Resistance
5 GEMMs for BRCA1-mutated breast cancer K14cre;p53 F/F tissue specific loss of p53 K14cre;Brca1 F/F ;p53 F/F tissue specific loss of p53 + Brca % tumor free T 50 = 290 days T 50 = 210 days Liu et al., PNAS 2007
6 GEMMs for BRCA1-mutated breast cancer K14cre;p53 F/F tissue specific loss of p53 K14cre;Brca1 F/F ;p53 F/F tissue specific loss of p53 + Brca1 p53 / (BRCA proficient) Brca1 / ;p53 / (BRCA1 null) Liu et al., PNAS 2007
7 BRCA1-deficient mouse mammary tumors resemble human BRCA1-associated breast cancer Solid carcinoma (IDC nos) High grade (III) Undifferentiated Pushing margins Triple negative (ER ;PR ;HER2 ) Genomic instability Solid carcinoma Adenomyoepithelioma 91% IDCIII Carcinosarcoma (EMT tumor) Liu et al., PNAS 2007
8 Therapy response and resistance in the BRCA1-null mammary tumor model BRCA1 null tumors relative tumor size control untreated cisplatin T1 cisplatin Time (days) T1 T2 T3 T4 T5 T6 T7 T2 T3 T4 T5 T6 T7 Rottenberg et al., PNAS 2007
9 Therapy response and resistance in the BRCA1-null mammary tumor model BRCA1 null tumors relative tumor size control untreated cisplatin T1 cisplatin T1 T2 T3 T4 T5 T6 T7 T2 T3 T4 T5 T6 T7 PARPi olaparib 700 T2 T3 600 T4 500 T5 400 T6 300 T Rottenberg et al., PNAS 2008 Time (days) T1
10 Novel BRCA1 mammary tumor models for therapy response and resistance K14cre; Brca1 F/F ; p53 F/F Genetic reversion Pgp activation Other
11 Novel BRCA1 mammary tumor models for therapy response and resistance C61G BRCA1 C61G K14cre; Brca1 F/F ; p53 F/F K14cre; Brca1 C61G/F ; p53 F/F Genetic reversion * Pgp activation Other
12 BRCA1-C61G tumors show poor response to PARPi BRCA1-C61G C61G No interaction with BARD1 BRCA proficient BRCA1 C61G BRCA1 null Drost et al., Cancer Cell 2011
13 BRCA1-C61G tumors show poor response to cisplatin BRCA1-C61G C61G No interaction with BARD1 BRCA proficient BRCA1 C61G BRCA1 null Drost et al., Cancer Cell 2011
14 Hypomorphic activity of BRCA1-C61G BRCA proficient BRCA1 C61G Rel % cells with >10 foci BRCA1 null BRCA proficient BRCA1 C61G BRCA1 null Drost et al., Cancer Cell 2011
15 Novel BRCA1 mammary tumor models for therapy response and resistance Mdr1 / BRCA1 C61G K14cre; Brca1 F/F ; p53 F/F ; Mdr1 / K14cre; Brca1 F/F ; p53 F/F K14cre; Brca1 Tr/F ; p53 F/F Genetic reversion Pgp activation X * Other
16 Acquired resistance to PARPi in the Pgp-deficient BRCA1 mammary tumor model Brca1 -/- ;p53 -/- Brca1 -/- ;p53 -/- ;Mdr1 -/- relative tumor size PARPi olaparib T1 T2 T3 T4 T5 T6 T Time (days) PARPi olaparib T1 T2 T3 T4 T5 T6 T7 T8 T9 PAR (pg/10mg protein) UD UD UD UD UD UD UD UD UD UD Sens Res Sens Res Sens Res T1 T3 T4 Control PARPi 30 min PARPi 7 days Jaspers et al., in prep.
17 Somatic 53BP1 mutations in PARPi-resistant tumors Tumor 3: 1bp insertion in exon 12 Tumor 5: duplication of 53BP1 exons sensitive resistant untreated Tumor 1 Tumor 3 Tumor 5 Jaspers et al., in prep. PARPi resistant
18 Loss of 53BP1 correlates with partial restoration of RAD51 foci formation IR BRCA proficient BRCA1 null control BRCA1 null PARPi resistant Jaspers et al., in prep.
19 Low 53BP1 expression is associated with triple-negative and BRCA1/2-mutated breast cancer Features Normal 53BP1 (%) Aberrant 53BP1(%) p * Not Triple-negative 861 (87.0) 14 (50.0) Triple-negative 129 (13.0) 14 (50.0) Non-BRCA1/ (94.0) 29 (76.3) BRCA1/2 69 (6.0) 9 (23.7) Bouwman et al., Nat Struct Mol Biol 2010
20 Screen for compounds with selective toxicity against BRCA2-deficient cells 97 of 1280 LOPAC compounds gave IC50s 5 compounds gave selective toxicity in BRCA2-deficient cells 2.5 Co-Correlation plot Increasing selective toxicity BRCA2+ vs Correlation: Chlorambucil Nimustine Melphalan Carboplatin BRCA Evers et al., Clin Cancer Res KP 3 33 KB2P 1 21 BRCA2+ vs. BRCA2-
21 In vivo validation in the BRCA1-null model BRCA proficient tumors BRCA1 null tumors Rottenberg et al., in prep.
22 Eradication of advanced BRCA1-like breast cancer by high-dose cross-linking chemotherapy >4 LN+ Standard: 5*FEC High dose: 4*FEC + 1*CTC TN tumors with sporadic like CGH profile TN tumors with BRCA1 like CGH profile high dose standard Vollebergh et al., Ann Oncol. 2010
23 Dose matters! Nimustine responses in the BRCA1 null mammary tumor model Time to relapse (%) mg/kg 22.5 mg/kg 15 mg/kg 7.5 mg/kg Latency (days) Rottenberg et al., in prep.
24 Studying epigenetic resistance mechanisms in primary breast cancer xenograft models Fresh tumor piece In vivo propagation Interventions Compare outgrowth to primary tumor: Histology, gene expression, acgh, BRCA1 status ter Brugge et al., in prep.
25 TNBC tumorgrafts with (epi)genetic BRCA1 loss T127 T162 T241 T250 BRCA1 status + Protein expression Promoter methylation yes yes no no Mutation no no no yes ter Brugge et al., in prep.
26 BRCA1-deficient TNBCs acquire resistance to PARPi ter Brugge et al., in prep.
27 Detection of RAD51 foci in FFPE sections T127 untreated T127 cis1 T127 cis2 Courtesy Nick Barker, ICR London ter Brugge et al., in prep.
28 BRCA1-2329delC TNBC xenografts acquire resistance via genetic reversion Wild type T250 T250 res1 T250 res2 * * * Wild-type T250 T250-res1 T250-res2 ACACTTTAACTGTTTCTAGTTTCTCTTCTTTTTCTTCTCTTGGAAGG ACACTTTAACT.TTTCTAGTTTCTCTTCTTTTTCTTCTCTTGGAAGG (1bp del) ACACTTTAACT.TTTCTAGTTTCTCTTCTT...GGAAGG (12bp del) ACACTTT...TTCTTCTCTTGGAAGG (24bp del)
29 TNBCs with BRCA1 methylation may acquire resistance via BRCA1 re-expression Loss of BRCA1 promoter methylation Retention of BRCA1 promoter methylation Only half of the therapy resistant tumors with BRCA1 re expression show loss of BRCA1 promoter methylation! ter Brugge et al., in prep.
30 De novo gene fusions drive BRCA1 re-expression in therapy-resistant T127 TNBC xenografts A functional role for chromotrypsis in therapy resistance? ter Brugge et al., in prep.
31 Partnerships foster translational research Clinic Lab Mouse clinic Diagnostics Treatment Diagnostics Treatment Follow up Follow up Pharma
32 Conclusions BRCA1 null mouse mammary tumors Tumors PARPi Tumors cisplatin Tumors nimustine Relapses PARPi Relapses cisplatin Cure Resistance
33 Conclusions : BRCA1/2 deficient PARPi sensitive : BRCA1/2 proficient PARPi resistant P gp activity? Type of BRCA1 mutation? 53BP1 loss? Genetic reversion? BRCA1 promoter methylation? Other factors? PARPi sensitive? PARPi resistant?
34 Acknowledgements Jos Jonkers Peter Bouwman Ute Boon Tanya Braumuller Karin de Visser Rinske Drost Janneke Jaspers Linda Henneman Sjors Kas Christiaan Klijn Sjoerd Klarenbeek Ewa Michalak Mark Pieterse Eva Schut-Kregel Petra Ter Brugge Eline Van der Burg Hanneke vd Gulden Marieke van de Ven Ellen Wientjens Sabine Linn Marieke Vollebergh Alumni Bastiaan Evers Henne Holstege Xiaoling Liu Piet Borst Sven Rottenberg Ariena Kersbergen Jelle Wesseling Petra Kristel AstraZeneca Marc O Connor Collaborators Alan Ashworth Nick Barker Jiri Bartek Jo Morris Shridar Ganesan Madalena Tarsounas
Dissection of breast cancer development and therapy resistance in mouse models. Jos Jonkers, Netherlands Cancer Institute, Amsterdam, The Netherlands
Dissection of breast cancer development and therapy resistance in mouse models Jos Jonkers, Netherlands Cancer Institute, Amsterdam, The Netherlands GEMMs of human cancer Genetically engineered mouse models
More informationEx vivo functional assays for Homologous Recombination deficiency in breast cancer. Dik C. van Gent
Ex vivo functional assays for Homologous Recombination deficiency in breast cancer Dik C. van Gent Breast cancer types treatments ER/PR: anti-hormonal therapy HER2: Herceptin Triple negative (TNBC): no
More information"BRCAness," PARP and the Triple-Negative Phenotype
"BRCAness," PARP and the Triple-Negative Phenotype Prof Alan Ashworth, FRS Disclosures for Professor Alan Ashworth, FRS Consulting Agreements GlaxoSmithKline, Pfizer Inc Patent AstraZeneca Pharmaceuticals
More informationGenetic modifications: from cells to organisms
Genetic modifications: from cells to organisms As an example: studying anti-cancer therapy resistance in genetically engineered mouse models (GEMMs) Sven Rottenberg Institute of Animal Pathology Images
More informationOverview and future horizons of PARP inhibitors in BRCAassociated. Judith Balmaña
Overview and future horizons of PARP inhibitors in BRCAassociated breast cancer Judith Balmaña PARP inhibitors: Mechanism of action Clinical development: Monotherapy In combination with chemotherapy Ongoing
More informationPARP Inhibitors: Patients Selection. Dr. Cristina Martin Lorente Hospital de la Santa Creu i Sant Pau Formigal, June 23th 2016
PARP Inhibitors: Patients Selection Dr. Cristina Martin Lorente Hospital de la Santa Creu i Sant Pau Formigal, June 23th 2016 OVARIAN CANCER (OC): MULTIPLES DISEASES Different types with different behaviour
More informationBrian T Burgess, DO, PhD, GYN Oncology Fellow Rachel W. Miller, MD, GYN Oncology
Brian T Burgess, DO, PhD, GYN Oncology Fellow Rachel W. Miller, MD, GYN Oncology Epithelial Ovarian Cancer - Standard Current Treatment: Surgery with De-bulking + Platinum-Taxane based Chemotherapy - No
More informationPHD STUDENTSHIP PROJECT PROPOSAL
The Institute of Cancer Research PHD STUDENTSHIP PROJECT PROPOSAL PROJECT DETAILS Project Title: Short Project Title: SUPERVISORY TEAM Primary Supervisor(s): Understanding therapeutic responses in BRCA
More informationUMC- Maastricht. UMC- Groningen Erasmus MC VUMC TOTAL. NKI UMC-Utrecht Leiden UMC. 245,000-Linn, PKAinduced. of ERa at serine 305 and
NKI UMC-Utrecht Leiden UMC UMC- Maastricht UMC- Groningen Erasmus MC VUMC TOTAL 224,000-Linn, PKAinduced high PAK1 levels is 224,000-van Diest, to tamoxifen in ER-positive in 2007 TOTAL 224,000 224,000
More information10/15/2012. Biologic Subtypes of TNBC. Topics. Topics. Histopathology Molecular pathology Clinical relevance
Biologic Subtypes of TNBC Andrea L. Richardson M.D. Ph.D. Brigham and Women s Hospital Dana-Farber Cancer Institute Harvard Medical School Boston, MA Topics Histopathology Molecular pathology Clinical
More informationPrevalence and clinical implications of BRCA1/2 germline mutations in Chinese women with breast cancer Yuntao Xie M.D., Ph.D.
Prevalence and clinical implications of BRCA1/2 germline mutations in Chinese women with breast cancer Yuntao Xie M.D., Ph.D. Hereditary Cancer Center, Peking University Cancer Hospital 1 Breast cancer
More informationPARP inhibitors for breast cancer
PARP inhibitors for breast cancer Mark Robson, MD Memorial Sloan Kettering Cancer Center Agenda Mechanism of action Clinical studies Resistance mechanisms Future directions Poly (ADP-ribose) Polymerases
More informationTriple Negative Breast Cancer
Triple Negative Breast Cancer Prof. Dr. Pornchai O-charoenrat Division of Head-Neck & Breast Surgery Department of Surgery Faculty of Medicine Siriraj Hospital Breast Cancer Classification Traditional
More informationBreast cancer: Molecular STAGING classification and testing. Korourian A : AP,CP ; MD,PHD(Molecular medicine)
Breast cancer: Molecular STAGING classification and testing Korourian A : AP,CP ; MD,PHD(Molecular medicine) Breast Cancer Theory: Halsted Operative breast cancer is a local-regional disease The positive
More informationCarcinoma mammario triple nega0ve Nuove acquisizioni biologiche. Giuseppe Curigliano MD PhD UNIMI & IEO
Carcinoma mammario triple nega0ve Nuove acquisizioni biologiche Giuseppe Curigliano MD PhD UNIMI & IEO Outline San Antonio Breast Cancer Symposium, December 5-9, 2017 The year of DNA Repair targe?ng Olaparib
More informationTriple-Negative Breast Cancer Time to Slice and Dice? Carsten Denkert, MD Charité University Hospital Berlin, Germany
Triple-Negative Breast Cancer Time to Slice and Dice? Carsten Denkert, MD Charité University Hospital Berlin, Germany Triple-Negative Breast Cancer (TNBC) 2018 Presentation Outline The molecular heterogeneity
More informationEvaluation of BRCA1/2 and homologous recombination defects in ovarian cancer and impact on clinical outcomes
Evaluation of BRCA1/2 and homologous recombination defects in ovarian cancer and impact on clinical outcomes Melinda S. Yates, PhD Department of Gynecologic Oncology & Reproductive Medicine University
More informationBreast cancer classification: beyond the intrinsic molecular subtypes
Breast cancer classification: beyond the intrinsic molecular subtypes Britta Weigelt, PhD Signal Transduction Laboratory CRUK London Research Institute Summary Breast cancer heterogeneity Molecular classification
More informationTriple Negative Breast Cancer. Eric P. Winer, MD Dana-Farber Cancer Institute Harvard Medical School Boston, MA October, 2008
Triple Negative Breast Cancer Eric P. Winer, MD Dana-Farber Cancer Institute Harvard Medical School Boston, MA October, 2008 Triple Negative Breast Cancer 15% 25% Triple Negative 20% HER2+ ER+ Low Grade
More informationProgress Update June 2017 Lay Summary Funding: $6,000,000 Grant Funded: July 2015 Dream Team Members Dream Team Leader:
SU2C -Ovarian Cancer Research Fund Alliance-National Ovarian Cancer Coalition Dream Team Translational Research Grant: DNA Repair Therapies for Ovarian Cancer AND SU2C Catalyst Merck-Supported Supplemental
More informationMedicina de precisión en cáncer de ovario: Determinación de BRCA germinal y somático
Medicina de precisión en cáncer de ovario: Determinación de BRCA germinal y somático Dra. Cristina Martin Lorente Hospital de la Santa Creu i Sant Pau. Barcelona Introduction Ovarian cancer is the fifth
More informationComputer Science, Biology, and Biomedical Informatics (CoSBBI) Outline. Molecular Biology of Cancer AND. Goals/Expectations. David Boone 7/1/2015
Goals/Expectations Computer Science, Biology, and Biomedical (CoSBBI) We want to excite you about the world of computer science, biology, and biomedical informatics. Experience what it is like to be a
More informationBiomarker for Response and Resistance in Ovarian Cancer
2016 대한부인종양학회제 31 차춘계학술대회 New Trends in Translational Research Biomarker for Response and Resistance in Ovarian Cancer Shin-Wha Lee, M.D., Ph.D. Department of Obstetrics and Gynecology ASAN Medical Center
More informationHistological Type. Morphological and Molecular Typing of breast Cancer. Nottingham Tenovus Primary Breast Cancer Study. Survival (%) Ian Ellis
Morphological and Molecular Typing of breast Cancer Ian Ellis Molecular Medical Sciences, University of Nottingham Department of Histopathology, Nottingham University Hospitals NHS Trust Histological Type
More informationUnderstanding and Optimizing Treatment of Triple Negative Breast Cancer
Understanding and Optimizing Treatment of Triple Negative Breast Cancer Edith Peterson Mitchell, MD, FACP Clinical Professor of Medicine and Medical Oncology Program Leader, Gastrointestinal Oncology Department
More informationDisclosure. Summary. Circulating DNA and NGS technology 3/27/2017. Disclosure of Relevant Financial Relationships. JS Reis-Filho, MD, PhD, FRCPath
Circulating DNA and NGS technology JS Reis-Filho, MD, PhD, FRCPath Director of Experimental Pathology, Department of Pathology Affiliate Member, Human Oncology and Pathogenesis Program Disclosure of Relevant
More informationTriple-Negative Breast Cancer
June 2017 Triple-Negative Breast Cancer Amir Sonnenblick, MD, PhD Sharett institute of oncology Hadassah-Hebrew university medical center, Jerusalem, Israel This presentation is the intellectual property
More informationAdvancing innovation towards breakthrough cancer therapies
Advancing innovation towards breakthrough cancer therapies LISTED EURONEXT Paris NASDAQ Copenhagen EPA: ONXEO 39th EORTC PAMM Winter meeting February 218 ASIDNA A FIRST-IN-CLASS COMPOUND TARGETING TUMOR
More informationDieta Brandsma, Department of Neuro-oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands
What is hot in breast cancer brain metastases? Dieta Brandsma, Department of Neuro-oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands 8th Annual Brain Metastases Research and Emerging Therapy
More informationCharacterisation of structural variation in breast. cancer genomes using paired-end sequencing on. the Illumina Genome Analyser
Characterisation of structural variation in breast cancer genomes using paired-end sequencing on the Illumina Genome Analyser Phil Stephens Cancer Genome Project Why is it important to study cancer? Why
More informationTriple Negative Breast cancer New treatment options arenowhere?
Triple Negative Breast cancer New treatment options arenowhere? Ofer Rotem, M.D., B.Sc. Breast Unit, Davidoff center Rabin Medical center October 2017 Case 6/2013 - M.D., 38 years old woman, healthy, no
More informationQuestion 1 A. ER-, PR-, HER+ B. ER+, PR+, HER2- C. ER-, PR+, HER2- D. ER-, PR-, HER2- E. ER-, PR+, HER2+
Triple Negative Breast Cancer Laura C. Collins, M.D. Department of Pathology Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA Question 1 The tumor depicted on the next slide
More informationInhibidores de PARP Una realidad? dónde y cuando?
Inhibidores de PARP Una realidad? dónde y cuando? Alberto Ocana Hospital Universitario Albacete Centro Regional Investigaciones Biomédicas CIC-Salamanca DNA repair mechanisms DNA is continually exposed
More informationTargeting DNA repair in BRCA 1/2 and Triple Negative Breast Cancer
Targeting DNA repair in BRCA 1/2 and Triple Negative Breast Cancer Andrew Tutt, MB ChB, PhD Consultant Oncologist/Director Breakthrough Breast Cancer Research Unit King s Health Partners Academic Health
More informationMolecular classification of breast cancer implications for pathologists. Sarah E Pinder
Molecular classification of breast cancer implications for pathologists Sarah E Pinder Courtesy of CW Elston Histological types Breast Cancer Special Types 17 morphological special types 25-30% of all
More informationConverting Novel Therapeutic Models into Early Phase Clinical Trials
Converting Novel Therapeutic Models into Early Phase Clinical Trials James H. Doroshow, M.D. Deputy Director for Clinical and Translational Research National Cancer Institute, NIH IOM National Cancer Policy
More informationGenetic Testing For Ovarian Cancer: When, How And Who? Judith Balmaña, MD, PhD University Hospital Vall d Hebron Barcelona, Spain
Genetic Testing For Ovarian Cancer: When, How And Who? Judith Balmaña, MD, PhD University Hospital Vall d Hebron Barcelona, Spain Why Would We Consider Genetic Testing in Patients With Ovarian Cancer?
More informationThe Evolving Role of Adjuvant Therapies
Therapy-predictive markers for adjuvant chemotherapy The Evolving Role of Adjuvant Therapies Micrometastasis Prognostic Markers (BRCA1) Cured No Further Tx Chemosensitive Rafael Rosell th European Perspectives
More informationSupplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Fong PC, Boss DS, Yap TA, et al. Inhibition of poly(adp-ribose)
More informationSpeakers. Text to be added
Speakers SESSION 1 Clinical status and perspectives for hereditary breast and ovarian cancer (HBOC) risk prediction. Fergus Couch Mayo Clinic Cancer Center and the Center for Individualized Medicine, Diana
More informationClinico- Pathological Features And Out Come Of Triple Negative Breast Cancer
Clinico- Pathological Features And Out Come Of Triple Negative Breast Cancer Dr. HassanAli Al-Khirsani, MBChB, CABM, F.I.C.M.S AL-Sadder teaching hospital, oncology unit Dr. Nasser Ghaly Yousif, MBChB,G.P.
More informationFISH mcgh Karyotyping ISH RT-PCR. Expression arrays RNA. Tissue microarrays Protein arrays MS. Protein IHC
Classification of Breast Cancer in the Molecular Era Susan J. Done University Health Network, Toronto Why classify? Prognosis Prediction of response to therapy Pathogenesis Invasive breast cancer can have
More informationBiology of Young Breast Cancer and Management in Pregnant Women
19 th BSMO Annual Meeting 2017 Breast Cancer Task Force Biology of Young Breast Cancer and Management in Pregnant Women Matteo Lambertini, MD ESMO Fellow Institut Jules Bordet, Brussels Diegem, Belgium
More informationDall istologia alla caratterizzazione biomolecolare
Il carcinoma ovarico: approccio multidisciplinare e prospettive terapeutiche Dall istologia alla caratterizzazione biomolecolare Anna Pesci Ospedale SC Don Calabria, Negrar anna.pesci@sacrocuore.it Ovarian
More informationNew Trials status update ATARI/NCRI
New Trials status update ATARI/NCRI Trial setting: advanced, recurrent gynaecological cancers clear cell, endometrioid, carcinosarcoma (ovarian and endometrial), cervical carcinoma Study Design: non-randomised,
More informationTriple Negative Breast Cancer: Part 2 A Medical Update
Triple Negative Breast Cancer: Part 2 A Medical Update April 29, 2015 Tiffany A. Traina, MD Breast Medicine Service Memorial Sloan Kettering Cancer Center Weill Cornell Medical College Overview What is
More informationENFERMEDAD AVANZADA Qué hacemos con el triple negativo? Nuevas aproximaciones
ENFERMEDAD AVANZADA Qué hacemos con el triple negativo? Nuevas aproximaciones Javier Cortes, Hospital Universitario Ramon y Cajal, Madrid Vall d Hebron Institute of Oncology (VHIO), Barcelona Triple Negative
More information10th French-Belgian ABC Meeting Brussels, October, 2012
Finding physiological functions of drug transporters using KO mice, LC-MS and transportomics Piet Borst Koen van de Wetering The Netherlands Cancer Institute 10th French-Belgian ABC Meeting Brussels, 19-20
More informationGermline Genetic Testing for Breast Cancer Risk
Kathmandu, Bir Hospital visit, August 2018 Germline Genetic Testing for Breast Cancer Risk Evidence-based Genetic Screening Rodney J. Scott Demography in New South Wales (total population ~ 7,000,000)
More informationBreast Cancer Statistics
1 in 8 Breast Cancer Statistics Incidence Mortality Prevalence 2 Breast Cancer Incidence Breast Cancer Mortality Breast Cancer Prevalence ~$100,000 Female Breast Anatomy Breasts consist mainly of fatty
More informationThe use of diagnostic FFPE material in cancer epidemiology research
The use of diagnostic FFPE material in cancer epidemiology research Neil O Callaghan Genetic Epidemiology Laboratory Department of Pathology The University of Melbourne www.pedigree.org.au Overview Who
More informationMolecular subtyping: how useful is it?
Molecular subtyping: how useful is it? Daniela E. Aust, Institute for Pathology, University Hospital Dresden, Germany Center for Molecular Tumor Diagnostics at the NCT-Partner Site Dresden CMTD Disclosure
More informationClinical Research on PARP Inhibitors and Triple-Negative Breast Cancer (TNBC)
Clinical Research on PARP Inhibitors and Triple-Negative Breast Cancer (TNBC) Eric P Winer, MD Disclosures for Eric P Winer, MD No real or apparent conflicts of interest to disclose Key Topics: PARP and
More informationGenomic tests to personalize therapy of metastatic breast cancers. Fabrice ANDRE Gustave Roussy Villejuif, France
Genomic tests to personalize therapy of metastatic breast cancers Fabrice ANDRE Gustave Roussy Villejuif, France Future application of genomics: Understand the biology at the individual scale Patients
More informationManagement of Inflammatory Breast Cancer: Collaboration is the path forward
Management of Inflammatory Breast Cancer: Collaboration is the path forward Massimo Cristofanilli, M.D., F.A.C.P. Professor of Medicine Associate Director of Translational Research and Precision Medicine
More information10/15/2012. Inflammatory Breast Cancer vs. LABC: Different Biology yet Subtypes Exist
Triple-Negative Breast Cancer: Optimizing Treatment for Locally Advanced Breast Cancer Beth Overmoyer MD Director, Inflammatory Breast Cancer Program Dana Farber Cancer Institute Overview Inflammatory
More informationRESISTANCE RELATIONSHIPS BETWEEN PLATINUM AND PARP-INHIBITORS IN OVARIAN CANCER.
RESISTANCE RELATIONSHIPS BETWEEN PLATINUM AND PARP-INHIBITORS IN OVARIAN CANCER. Britta Stordal 1, Yidong Chen 2, Angela Farrelly 3, Danielle Gallagher 3, Steven Busschots 1, Mattia Cremona 3, Mark Carey
More informationPresent Role of Immunohistochemistry in the. Subtypes. Beppe Viale European Institute of Oncology University of Milan Milan-Italy
Present Role of Immunohistochemistry in the Classification of Molecular Subtypes Beppe Viale European Institute of Oncology University of Milan Milan-Italy We know it is many diseases Breast cancer is
More informationEnterprise Interest None
Enterprise Interest None What are triple negative breast cancers? A synopsis of their histological patterns Ian Ellis Molecular Medical Sciences, University of Nottingham Department of Histopathology,
More informationMyriad Genetics mychoice HRD Update 06/30/2016
Myriad Genetics mychoice HRD Update 06/30/2016 1 Forward Looking Statements Some of the information presented here today may contain projections or other forward-looking statements regarding future events
More informationImmunotherapy for Breast Cancer. Aurelio B. Castrellon Medical Oncology Memorial Healthcare System
Immunotherapy for Breast Cancer Aurelio B. Castrellon Medical Oncology Memorial Healthcare System Conflicts Research support : Cascadian therapeutics, Puma biotechnology, Odonate therapeutics, Pfizer,
More informationXII Michelangelo Foundation Seminar
XII Michelangelo Foundation Seminar The opportunity of the neoadjuvant approach L. Gianni, Milan, I XII Michelangelo Foundation Seminar Milano, October 12, 2012 The opportunity of the neoadjuvant approach
More informationMolecular Subtyping of Endometrial Cancer: A ProMisE ing Change
Molecular Subtyping of Endometrial Cancer: A ProMisE ing Change Charles Matthew Quick, M.D. Associate Professor of Pathology Director of Gynecologic Pathology University of Arkansas for Medical Sciences
More informationAbstract # 1503: Predisposing germline mutations in high grade ER+ HER2- breast cancer patients diagnosed age < 50
Abstract # 1503: Predisposing germline mutations in high grade ER+ HER2- breast cancer patients diagnosed age < 50 Garber JE 1, Tung NM 2, Elkin EP 3, Allen BA 3, Singh NA 3, Wenstrup R 3, Hartman AR 3,
More informationUniversity of Groningen
University of Groningen Therapeutic targeting and patient selection for cancers with homologous recombination defects Talens, Francien; Jalving, Mathilde; Gietema, Jourik A.; van Vlugt, Marcel A. T. M.
More informationRecent advances in breast cancers
Recent advances in breast cancers Breast cancer is a hetrogenous disease due to distinct genetic alterations. Similar morphological subtypes show variation in clinical behaviour especially in response
More informationUvA-DARE (Digital Academic Repository) Novel treatment strategies for hereditary breast cancer Evers, B. Link to publication
UvA-DARE (Digital Academic Repository) Novel treatment strategies for hereditary breast cancer Evers, B. Link to publication Citation for published version (APA): Evers, B. (29). Novel treatment strategies
More informationA case of a BRCA2-mutated ER+/HER2 breast cancer during pregnancy
ESMO Preceptorship Programme Breast Cancer Lisbon 16,17 September 2016 Emanuela Risi Sandro Pitigliani Medical Oncology Department Hospital of Prato, Istituto Toscano Tumori, Prato, Italy A case of a BRCA2-mutated
More informationComprehensive Genomic Profiling, in record time. Accurate. Clinically Proven. Fast.
Comprehensive Genomic Profiling, in record time Accurate. ly Proven. Fast. PCDx advantages Comprehensive genomic profiling, in record time PCDx Comprehensive Genomic Profiling (CGP) provides precise information
More informationSupplementary Figure 1: Comparison of acgh-based and expression-based CNA analysis of tumors from breast cancer GEMMs.
Supplementary Figure 1: Comparison of acgh-based and expression-based CNA analysis of tumors from breast cancer GEMMs. (a) CNA analysis of expression microarray data obtained from 15 tumors in the SV40Tag
More informationTNBC: What s new Déjà vu All Over Again? Lucy R. Langer, MD MSHS Compass Oncology - SABCS 2016 Review February 21, 2017
TNBC: What s new Déjà vu All Over Again? Lucy R. Langer, MD MSHS Compass Oncology - SABCS 2016 Review February 21, 2017 The problem with TNBC 1. Generally more aggressive 2. ONLY chemotherapy 3. No other
More informationCharacterization of the mouse and human breast cancer genome Holstege, H.
UvA-DARE (Digital Academic Repository) Characterization of the mouse and human breast cancer genome Holstege, H. Link to publication Citation for published version (APA): Holstege, H. (2010). Characterization
More informationAVANCES EN EL TRATAMIENTO SISTEMICO DE LOS TUMORES BRCA-DEFICIENTES
AVANCES EN EL TRATAMIENTO SISTEMICO DE LOS TUMORES BRCA-DEFICIENTES Dra. Judith Balmaña Servicio de Oncología Médica Hospital Universitario Vall Hebron Barcelona jbalmana@vhio.net Preclinical evidence
More informationTriple Negative Breast Cancer
GASCO 2016 San Antonio Breast Cancer Symposium Review Triple Negative Breast Cancer Amelia Zelnak, MD, MSc Atlanta Cancer Care Northside Hospital Cancer Institute Disclosures: consultant for Novartis,
More informationThe cancer connection: BRCA1 and BRCA2 tumor suppression in mice and humans
(2002) 21, 8994 9007 ª 2002 Nature Publishing Group All rights reserved 0950 9232/02 $25.00 www.nature.com/onc The cancer connection: BRCA1 and BRCA2 tumor suppression in mice and humans Mary Ellen Moynahan*,1
More informationNew: P077 BRCA2. This new probemix can be used to confirm results obtained with P045 BRCA2 probemix.
SALSA MLPA KIT P045-B2 BRCA2/CHEK2 Lot 0410, 0609. As compared to version B1, four reference probes have been replaced and extra control fragments at 100 and 105 nt (X/Y specific) have been included. New:
More informationComputational Investigation of Homologous Recombination DNA Repair Deficiency in Sporadic Breast Cancer
University of Massachusetts Medical School escholarship@umms Open Access Articles Open Access Publications by UMMS Authors 11-16-2017 Computational Investigation of Homologous Recombination DNA Repair
More informationLack of Genomic Heterogeneity at High-Resolution acgh between Primary Breast Cancers and Their Paired Lymph Node Metastases
Lack of Genomic Heterogeneity at High-Resolution acgh between Primary Breast Cancers and Their Paired Lymph Node Metastases Marieke A. Vollebergh 1,4., Christiaan Klijn 1., Philip C. Schouten 1, Jelle
More informationRicombinazione omologa nel carcinoma ovarico: BRCA e oltre. F. Raspagliesi MD
Ricombinazione omologa nel carcinoma ovarico: BRCA e oltre F. Raspagliesi MD raspagliesi@istitutotumori.mi.it BRCA molecular signature in ovarian cancer In a pooled analysis of 26 observational studies
More informationPrognostic significance of stroma tumorinfiltrating lymphocytes according to molecular subtypes of breast cancer
Prognostic significance of stroma tumorinfiltrating lymphocytes according to molecular subtypes of breast cancer Hee Jung Kwon, Nuri Jang, Min Hui Park, Young Kyung Bae Department of Pathology, Yeungnam
More informationTumor suppressor genes D R. S H O S S E I N I - A S L
Tumor suppressor genes 1 D R. S H O S S E I N I - A S L What is a Tumor Suppressor Gene? 2 A tumor suppressor gene is a type of cancer gene that is created by loss-of function mutations. In contrast to
More informationMaram Abdaljaleel, MD Dermatopathologist and Neuropathologist University of Jordan, School of Medicine
Maram Abdaljaleel, MD Dermatopathologist and Neuropathologist University of Jordan, School of Medicine The most common non-skin malignancy of women 2 nd most common cause of cancer deaths in women, following
More informationMolEcular Taxonomy of BReast cancer International Consortium (METABRIC)
PERSPECTIVE 1 LARGE SCALE DATASET EXAMPLES MolEcular Taxonomy of BReast cancer International Consortium (METABRIC) BC Cancer Agency, Vancouver Samuel Aparicio, PhD FRCPath Nan and Lorraine Robertson Chair
More informationVirtual Journal Club. Ovarian Cancer. Reference Slides. Platinum-Sensitive Recurrent Ovarian Cancer: Making the Most of Emerging Targeted Therapies
Virtual Journal Club Ovarian Cancer Reference Slides Platinum-Sensitive Recurrent Ovarian Cancer: Making the Most of Emerging Targeted Therapies Mansoor R. Mirza, MD Copenhagen University Hospital Rigshospitalet
More informationTriple negative breast cancer -neoadjuvant and adjuvant systemic therapy
Triple negative breast cancer -neoadjuvant and adjuvant systemic therapy Sung-Bae Kim, MD, PhD Department of Oncology Asan Medical Center University of Ulsan College of Medicine Seoul, Korea DISCLOSURE
More informationChapter 1 Sensitivity and acquired resistance of BRCA1;p53-deficient mouse mammary tumors to the topoisomerase I inhibitor topotecan
Chapter 1 Sensitivity and acquired resistance of BRCA1;p53-deficient mouse mammary tumors to the topoisomerase I inhibitor topotecan Serge A.L. Zander, Ariena Kersbergen, Eline van der Burg, Niels de Water,
More informationNew Avenues for the development and evaluation of therapy: Complex, multi-pronged, not one size fitting all
New Avenues for the development and evaluation of therapy: Complex, multi-pronged, not one size fitting all Antoine Yver MD MSC Senior VP & Head Oncology Global Medicines Development AstraZeneca, Gaithersburg
More informationTherapeutic Targets for Triple- Negative Breast Cancer: Focus on Platinums and EGFR Inhibition
Therapeutic Targets for Triple- Negative Breast Cancer: Focus on Platinums and EGFR Inhibition Lisa A Carey, MD Disclosures for Lisa A Carey, MD No real or apparent conflicts of interest to disclose Basal-Like
More informationElena Martinez, PhD & Bernard Futscher, PhD (co-pis) University of Arizona Arizona Cancer Center 1U01CA153086
Elena Martinez, PhD & Bernard Futscher, PhD (co-pis) University of Arizona Arizona Cancer Center 1U01CA153086 Hispanic population in U.S. is largely underserved and underrepresented in research studies
More informationIJC International Journal of Cancer
IJC International Journal of Cancer Short Report Oncotype Dx recurrence score among BRCA1/2 germline mutation carriers with hormone receptors positive breast cancer Naama Halpern 1, Amir Sonnenblick 2,
More informationPREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland
AD Award Number: W81XWH- TITLE: PRINCIPAL INVESTIGATOR: CONTRACTING ORGANIZATION: REPORT DATE: TYPE OF REPORT: Annual PREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland
More informationMammaPrint, the story of the 70-gene profile
MammaPrint, the story of the 70-gene profile René Bernards Professor of Molecular Carcinogenesis The Netherlands Cancer Institute Amsterdam Chief Scientific Officer Agendia Amsterdam The breast cancer
More informationA New String to the Bow in the Treatment of Advanced Ovarian Cancer Bradley J. Monk, MD, FACS, FACOG
A New String to the Bow in the Treatment of Advanced Ovarian Cancer Bradley J. Monk, MD, FACS, FACOG Arizona Oncology (US Oncology Network) Professor, Gynecologic Oncology University of Arizona and Creighton
More informationRecent Update in Management of Breast Cancer: Medical Oncology. Jin Hee Ahn, M.D., PhD. 23-April-2015
2015 GBCC & 4 th IBCS 1/37 Recent Update in Management of Breast Cancer: Medical Oncology Jin Hee Ahn, M.D., PhD. 23-April-2015 Department of Oncology, Asan Medical Center, UUCM, Seoul, Korea 2/37 3/37
More informationInterpretation of p53 Immunostains. P53 Mutations are Ubiquitous in High Grade Serous Carcinoma. Diffuse strong positive nuclear staining
Stains for Tumor Classification p53 p16 WT1 HMGA2 P53 Mutations are Ubiquitous in High Grade Serous Carcinoma Source Ahmed et al Australian Ovarian Cancer Study Cancer Genome Atlas Research Network Cases
More informationMolecular Classification of Triple-Negative Breast Cancer (TNBC) Aleix Prat, MD
Molecular Classification of Triple-Negative Breast Cancer (TNBC) Emerging genomic and clinical data Aleix Prat, MD Postdoctoral Research Associate at Perou Lab Lineberger Comprehensive Cancer Center University
More informationANALYTISCHE STRATEGIE Tissue Imaging. Bernd Bodenmiller Institute of Molecular Life Sciences University of Zurich
ANALYTISCHE STRATEGIE Tissue Imaging Bernd Bodenmiller Institute of Molecular Life Sciences University of Zurich Quantitative Breast single cancer cell analysis Switzerland Brain Breast Lung Colon-rectum
More informationMRC-Holland MLPA. Description version 18; 09 September 2015
SALSA MLPA probemix P090-A4 BRCA2 Lot A4-0715, A4-0714, A4-0314, A4-0813, A4-0712: Compared to lot A3-0710, the 88 and 96 nt control fragments have been replaced (QDX2). This product is identical to the
More informationRecurrence, new primary and bilateral breast cancer. José Palacios Calvo Servicio de Anatomía Patológica
Recurrence, new primary and bilateral breast cancer José Palacios Calvo Servicio de Anatomía Patológica Ipsilateral Breast Tumor Relapse (IBTR) IBTR can occur in approximately 5 20% of women after breast-conserving
More informationHow to address tumour heterogeneity in next generation oncology trials
How to address tumour heterogeneity in next generation oncology trials Cihangir YANDIM, PhD Research Associate in Cancer Therapeutics and Clinical Sciences Dr. Cihangir Yandim - CTIP 2016, Hamburg 1 Founded
More information